We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Oncologic Drugs Advisory Committee has voted 10–4 to recommend approval of Allos Therapeutics’ Folotyn in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).